FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region
FDA has announced that bebtelovimab is not currently authorized for emergency use in any region of the US.
FDA announced on Nov. 30, 2022 that bebtelovimab is not currently authorized for emergency use in any region of the United States because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1, according to data included in the Health Care Provider Fact Sheet.
Commercial distribution of bebtelovimab has been halted by Eli Lilly and its authorized distributers until further notice by FDA. The Administration for Strategic Preparedness and Response (ASPR) has also paused the fulfillment of any pending requests under its Bebtelovimab Product Replacement Initiative.
The US government has recommended all product be retained in the event that SARS-CoV-2 variants susceptible to bebtelovimab become more prevalent in the future in the US. These variants are currently circulating at lower prevalence.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
